Catálogo de publicaciones - revistas

<jats:sec><jats:title>Objective:</jats:title><jats:p> We aimed to explore psychiatry trainees’ perspectives on clinical teaching and supervision as well as how this might be improved. </jats:p></jats:sec><jats:sec><jats:title>Method:</jats:title><jats:p> New Zealand trainees ( n=51) completed online the Maastricht Clinical Teaching Questionnaire (MCQT) and three open-ended questions. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> The majority rated ‘agree’ or ‘strongly agree’ to all items of the MCQT. Weaknesses in the feedback process including observation, feedback provision, and formulating learning goals were highlighted. College training requirements and workplace environment were identified as factors impacting on clinical teaching and supervision. </jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p> A model was proposed to enhance awareness of the various factors involved in the feedback process. </jats:p></jats:sec>

<jats:sec><jats:title>Objective</jats:title><jats:p> Cariprazine is the third partial dopamine agonist now available in Australia. This paper will review the properties, evidence and likely clinical place of cariprazine. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> Cariprazine is a partial agonist with high affinity at dopamine D<jats:sub>2</jats:sub> and D<jats:sub>3</jats:sub> receptors, partial agonism at 5HT<jats:sub>1a</jats:sub> receptors, moderate 5HT<jats:sub>2a</jats:sub> and H<jats:sub>1</jats:sub> antagonism and no anticholinergic activity. It is rapidly absorbed, is unaffected by food, achieves a peak plasma level in 4–8 hours and has high bioavailability. The half-life of cariprazine and its metabolites is long (7–8 days); steady state occurs in 4–8 weeks. It is hepatically metabolized via 3A4 cytochrome enzymes. Cariprazine is an effective antipsychotic in acute schizophrenia in both short and longer placebo-controlled studies. Cariprazine appears to have small advantages in negative symptoms of schizophrenia. While not approved for bipolar disorder, cariprazine is effective in mania and mixed states but requires doses higher than current maximums recommended. Cariprazine causes more akathisia than aripiprazole or brexpiprazole but is less prone to insomnia, weight gain and sedation. Risks for hyperprolactinaemia and QT<jats:sub>c</jats:sub> prolongation are low. Cariprazine is another ‘metabolically-friendly’ antipsychotic for schizophrenia, with advantages for those with negative symptoms, mood symptoms or problems with adherence. </jats:p></jats:sec>